{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:42:43Z","timestamp":1779248563791,"version":"3.51.4"},"reference-count":61,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Historically, systemic therapy has been the primary treatment for metastatic prostate cancer (MPC), with radiotherapy and surgery reserved for palliation. The recent literature suggests that adding local therapy (i.e., radiotherapy or surgery) to systemic therapy may improve survival for MPC patients with low metastatic burden (LMB). While some evidence supports the use of early intervention with local therapy targeting both the primary tumor and limited metastatic sites, the definition of LMB disease requires further clarification. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans play a vital role in staging MPC because they offer superior sensitivity and specificity compared to conventional imaging. PSMA PET thus improves patient selection and helps direct treatment planning. Local therapy in MPC can be separated into the treatment of primary and metastatic tumors. Furthermore, treatment of both the primary tumor and metastases can be managed using either radiotherapy or surgical intervention. Studies exploring the use of local therapy for both the primary tumor and oligometastatic sites have demonstrated promising clinical outcomes in patients with LMB or oligometastatic disease. This review provides a detailed description of the current optimal management of patients with metastatic prostate cancer with limited disease.<\/jats:p>","DOI":"10.3390\/cancers18030450","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:09:22Z","timestamp":1769771362000},"page":"450","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Optimal Management of Patients with Prostate Cancer with Oligometastatic Disease and Low Metastatic Burden in the PSMA-PET Era"],"prefix":"10.3390","volume":"18","author":[{"given":"Menal","family":"Bhandari","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Lasko","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9261-6109","authenticated-orcid":false,"given":"Jacob","family":"Pozin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Chang","sequence":"additional","affiliation":[{"name":"Radiation Oncology Service, Hunter Holmes McGuire VA Medical Center, Richmond, VA 23249, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-0884","authenticated-orcid":false,"given":"Hann-Hsiang","family":"Chao","sequence":"additional","affiliation":[{"name":"Radiation Oncology Service, Hunter Holmes McGuire VA Medical Center, Richmond, VA 23249, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Henry","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas G.","family":"Nickols","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Ritter","sequence":"additional","affiliation":[{"name":"Radiation Oncology Service, Hunter Holmes McGuire VA Medical Center, Richmond, VA 23249, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph K.","family":"Salama","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek A.","family":"Solanki","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"ref_1","first-page":"10","article-title":"Cancer Statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Chai, Z., Yan, S., Li, H., Dong, X., Li, S., Fan, Y., Dong, Z., He, Z., Zhou, J., and Lei, P. (2025). Temporal trends and regional disparities in prostate cancer mortality in the United States, 1999\u20132023: An analysis of the CDC WONDER database. BMC Public Health, 25.","DOI":"10.1186\/s12889-025-25694-6"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastasis revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.18632\/oncotarget.3455","article-title":"The biology and treatment of oligometastatic cancer","volume":"6","author":"Reyes","year":"2015","journal-title":"Oncotarget"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e25417","DOI":"10.1097\/MD.0000000000025417","article-title":"The meta-analysis of the effect of 68Ga-PSMA-PET\/CT diagnosis of prostatic cancer compared with bone scan","volume":"100","author":"Zhao","year":"2021","journal-title":"Medicine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.clgc.2018.07.009","article-title":"68Ga-PSMA PET\/CT Replacing Bone Scan in the Initial Staging of Skeletal Metastasis in Prostate Cancer: A Fait Accompli?","volume":"16","author":"Lengana","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomized, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A Phase 2\/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET\/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","article-title":"Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial","volume":"7","author":"Hope","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic Performance of 18F-DCFPyL-PET\/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.2967\/jnumed.117.192476","article-title":"Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer","volume":"58","author":"Hope","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1097\/RLU.0000000000005284","article-title":"Evaluation of Treatment Outcomes of Prostate Cancer Patients with Lymph Node Metastasis Treated With Definitive Radiotherapy: Comparative Analysis of PSMA PET\/CT and Conventional Imaging","volume":"49","author":"Onal","year":"2024","journal-title":"Clin. Nucl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.eururo.2013.03.055","article-title":"Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: Results from a randomised phase 3 study by the South European Uroncological Group","volume":"66","author":"Santos","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jamaoncol.2015.2895","article-title":"Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis","volume":"1","author":"Magnan","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.eururo.2023.04.002","article-title":"The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES","volume":"84","author":"Armstrong","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e42318","DOI":"10.1097\/MD.0000000000042318","article-title":"Systemic treatment of metastatic castration-sensitive prostate cancer: A meta-analysis of efficacy and safety","volume":"104","author":"Zhang","year":"2025","journal-title":"Medicine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: Long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","article-title":"Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: A systematic review and meta-analysis of individual participant data from randomised trials","volume":"24","author":"CVale","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.3892\/or.2015.4319","article-title":"Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer","volume":"34","author":"Cifuentes","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.urolonc.2017.01.001","article-title":"Role of radical prostatectomy in metastatic prostate cancer: A review","volume":"35","author":"Metcalfe","year":"2017","journal-title":"Urol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"BSR20171379","DOI":"10.1042\/BSR20171379","article-title":"The role of radical prostatectomy for the treatment of metastatic prostate cancer: A systematic review and meta-analysis","volume":"38","author":"Wang","year":"2018","journal-title":"Biosci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.juro.2014.09.089","article-title":"Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: Results of a feasibility and case-control study","volume":"193","author":"Heidenreich","year":"2015","journal-title":"J. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.urology.2017.02.051","article-title":"Cytoreductive Prostatectomy for Metastatic Prostate Cancer: First Lessons Learned From the Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) Trial","volume":"106","author":"Poelaert","year":"2017","journal-title":"Urology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.prnil.2018.10.002","article-title":"Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer","volume":"7","author":"Yuh","year":"2019","journal-title":"Prostate Int."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Parker, C.C., James, N.D., Brawley, C.D., Clarke, N.W., Ali, A., Amos, C.L., Attard, G., Chowdhury, S., Cook, A., and Cross, W. (2022). Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLoS Med., 19.","DOI":"10.1371\/journal.pmed.1003998"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","article-title":"Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial","volume":"75","author":"Boeve","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.euf.2022.10.013","article-title":"Surgical Metastasectomy for Visceral and Bone Prostate Cancer Metastases: A Mini-Review","volume":"9","author":"Rajwa","year":"2023","journal-title":"Eur. Urol. Focus"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial","volume":"36","author":"Ost","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial","volume":"38","author":"Palma","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6376","DOI":"10.1158\/1078-0432.CCR-21-2510","article-title":"Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET\/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","article-title":"The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies","volume":"85","author":"Miszczyk","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.eururo.2024.01.021","article-title":"Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial","volume":"85","author":"Nikitas","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.eururo.2024.02.008","article-title":"Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer","volume":"86","author":"Nickols","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): A randomised, open-label, phase 2 clinical trial","volume":"26","author":"Marvaso","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.euo.2024.03.010","article-title":"Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer","volume":"7","author":"Deek","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1200\/JCO.23.00985","article-title":"Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)","volume":"41","author":"Francolini","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S1470-2045(25)00351-1","article-title":"Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): A multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Niazi","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1200\/JCO-25-01553","article-title":"177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study","volume":"43","author":"Kishan","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO-25-00131","article-title":"Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jamaoncol.2015.4350","article-title":"Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","article-title":"Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): A phase 2, open-label, randomised controlled trial","volume":"26","author":"Ost","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Mader, N., Schoeler, C., Pezeshkpour, N., Klimek, K., Groener, D., Happel, C., Tselis, N., Mandel, P., Gr\u00fcnwald, F., and Sabet, A. (2023). Intermittent Radioligand Therapy with 177Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer. Cancer, 15.","DOI":"10.3390\/cancers15184605"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/14737159.2023.2192351","article-title":"Radiomics and theranostics with molecular and metabolic probes in prostate cancer: Toward a personalized approach","volume":"23","author":"Filippi","year":"2023","journal-title":"Expert Rev. Mol. Diagn"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/3\/450\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:19:58Z","timestamp":1769771998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/3\/450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":61,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cancers18030450"],"URL":"https:\/\/doi.org\/10.3390\/cancers18030450","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}